Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, formerly AMG 133 -, an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. In people living with obesity or overweight without Type 2 diabetes, MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau, indicating the potential for further weight loss beyond 52 weeks. People living with obesity or overweight and Type 2 diabetes, who typically lose less weight on GLP-1 therapies, achieved up to ~17% average weight loss, also without a weight loss plateau, and lowered their average hemoglobin A1C by up to 2.2% at week 52.A weight loss plateau was not observed, again indicating the potential for further weight loss beyond 52 weeks. MariTide also demonstrated robust and clinically meaningful improvements in cardiometabolic parameters. There were no significant increases in free fatty acids. There was no association between the administration of MariTide and bone mineral density changes. The most common adverse events in the Phase 2 study were gastrointestinal related, including nausea, vomiting and constipation. The incidence of nausea and vomiting was substantially reduced with dose escalation. Data from this Phase 2 study will be presented at a future medical congress and submitted for publication. The ongoing Part 2 of the Phase 2 study is investigating MariTide beyond 52 weeks to evaluate further weight loss with continued treatment, weight maintenance through less frequent or lower dosing and durability of weight loss after discontinuation of MariTide. MariTide is produced in Amgen’s manufacturing network.